AVALIAÇÃO DA PROTEÍNA HBZ NO DESENVOLVIMENTO DA LEUCEMIA/LINFOMA DE CÉLULAS T DO ADULTO: UMA REVISÃO SISTEMÁTICA
DOI:
https://doi.org/10.22481/rsc.v14i4.4445Resumen
A proteína HTLV-1 bzip factor (HBZ) é produzida pelas células infectadas pelo HTLV-1 e sua expressão se dá de forma constante em células de indivíduos com Leucemia/Linfoma de Células T do Adulto (ATLL). Essa patologia é grave e, apesar de existir tratamentos que reduzam os sintomas e aumentem a sobrevida do paciente, ainda não existe cura conhecida para a infecção pelo HTLV-1. A HBZ foi descrita como uma das principais proteínas virais que induzem proliferação e imortalização celular da célula infectada pelo HTLV-1. Como a HBZ é sempre expressa em células de pacientes com ATLL, é importante discutir os mecanismos de atuação dessa proteína para auxiliar estudos futuros sobre tratamento e prevenção de doenças provocadas pelo HTLV-1. Portanto, esse trabalho possui como objetivo principal investigar as vias de atuação dessa proteína no desenvolvimento da ATLL. Essa revisão sistemática foi realizada a partir de artigos encontrados na plataforma de busca do PubMed. Foram encontrados 61 artigos, destes 20 foram incluídos e seus dados foram coletados. A partir dos dados obtidos, é possível concluir que proteína HBZ é importante no desenvolvimento de ATLL ao contribuir na proliferação, imortalização e sobrevivência das células infectadas. Porém ainda não está claro se a HBZ participa do mecanismo inicial de desenvolvimento da ATLL.
Descargas
Citas
Gallo RC. The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology. 2005; 2(1): 17.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 2012; 3: 388.
Carneiro-Proietti ABF, et al. Infecção e doença pelos vírus linfotrópicos humanos de células T (HTLV-I/II) no Brasil. Rev. Soc. Bras. Med. Trop. 2002; 35(5): 499-508.
Karimi M, et al. Role of the HTLV-1 viral factors in the induction of apoptosis. Biomed. Pharmacother. 2017; 85: 334-347.
Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer. 2007; 7(4): 270-280.
Giam CZ, Semmes OJ. HTLV-1 infection and adult T-cell leukemia/lymphoma — a tale of two proteins: Tax and HBZ. Viruses. 2016; 8(6): 161.
Gaudray G, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol. 2002; 76(24): 12813-12822.
Silva FA, et al. Leucemia-linfoma de células T do adulto no Brasil: epidemiologia, tratamento e aspectos controversos. Rev. Bras. Cancerol. 2002; 48(4): 585-595.
Mesnard JM, et al. Roles of HTLV-1 basic zip factor (HBZ) in viral chronicity and leukemic transformation. Viruses. 2015; 7(12): 6490-6505.
Taguchi H, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with G-CSF support. JAIDS. 1996; 12(2): 182-186.
Tsukasaki K, et al. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int. J. Hematol. 2003; 77(2): 164-170.
Nasr R, et al. Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?. Viruses. 2011; 3(6): 750-769.
Utsunomiya A, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 27(1): 15-20.
Edwards D, et al. Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence. Viruses. 2011; 3(6): 861-885.
Satou Y, et al. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 2006; 103(3): 720-725.
Sugata K, et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015; 126(9): 1095-1105.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7): e1000097.
Lairmore MD, Haines R, Anupam R. Mechanisms of human T-lymphotropic virus type 1 transmission and disease. Curr. Opin. Virol. 2012; 2(4): 474-481.
Ma Y, et al. The HTLV-1 HBZ protein inhibits cyclin D1 expression through interacting with the cellular transcription factor CREB. Mol. Biol. Rep. 2013; 40(10): 5967-5975.
Mukai R, Ohshima T. HTLV-1 bZIP factor suppresses the centromere protein B (CENP-B)-mediated trimethylation of histone H3K9. J. Gen. Virol. 2015; 96(1): 159-164.
Raval GU, et al. Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL. Retrovirology. 2015; 12: 59.
Vernin C, et al. HTLV-1 bZIP factor HBZ promotes cell proliferation and genetic instability by activating OncomiRs. Cancer Res. 2014; 74(21): 6082-6093.
Borowiak M, et al. HTLV-1 bZIP factor impedes the menin tumor suppressor and upregulates JunD-mediated transcription of the hTERT gene. Carcinogenesis. 2013; 34(11): 2664-2672.
Shay JW, et al. Telomerase and cancer. Hum. Mol. Genet. 2001; 10(7): 677-685.
Wright DG, et al. Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1. Oncotarget. 2016; 7(2): 1687-1706.
Mukai R, Ohshima T. HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm. Oncogene. 2014; 33(18): 2317-2328.
Mukai R, Ohshima T. Enhanced Stabilization of MCL1 by the Human T-Cell Leukemia Virus Type 1 bZIP Factor Is Modulated by Blocking the Recruitment of Cullin 1 to the SCF Complex. Mol. Cell. Biol. 2016; 36(24): 3075-3085.
Tanaka-Nakanishi A, et al. HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res. 2014; 74(1): 188-200.
Arnold J, et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense encoded protein of HTLV-1. Blood. 2006; 107(10): 3976-3982.
Satou Y, et al. HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog. 2011; 7(2): e1001274.
Ma G, et al. HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene. 2013; 32(36): 4222-4230.
Panfil AR, et al. Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. J. Virol. 2016; 90(7): 3760-3772.
Polakowski N, et al. HBZ stimulates brain-derived neurotrophic factor/TrkB autocrine/paracrine signaling to promote survival of HTLV-1-Infected T cells. J. Virol. 2014; 88(22): 13482-13494.
Narulla MS, et al. Positive and negative regulation of type I interferons by the human T-cell leukemia virus antisense protein HBZ. J. Virol. 2017; 91(20): e00853-17.
Ma Y, et al. HTLV-1 basic leucine zipper factor downregulates cyclin D1 expression via interactions with NF-kappaB. Int. J. Mol. Med. 2017; 39(3): 764-770.
Kim YM, et al. The HTLV-1 Tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene. 2010; 29(14): 2142-2152.
Laverdure S, et al. Permissive sense and antisense transcription from the 5′ and 3′ long terminal repeats of human T-cell leukemia virus type 1. J. Virol. 2016; 90(7): 3600-3610.
Gazon H, et al. Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3′ long terminal repeat. J. Virol. 2012; 86(17): 9070-9078.
Iwanaga M, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010; 116(8): 1211-1219.
Akbarin MM, et al. Evaluation of the role of TAX, HBZ, and HTLV-1 proviral load on the survival of ATLL patients. Blood Res. 2017; 52(2): 106-111.
Shiohama Y, et al. Absolute quantification of HTLV-1 basic leucine zipper factor (HBZ) protein and its plasma antibody in HTLV-1 infected individuals with different clinical status. Retrovirology. 2016; 13(1): 29.
Enose-Akahata Y, et al. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals. Retrovirology. 2013; 10(1): 19.
Suemori K, et al. HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. J. Gen. Virol. 2009; 90(8): 1806-1811.
Narita T, et al. HTLV-1 bZIP Factor–Specific CD4 T Cell Responses in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation. J. Immunol. 2014; 192(3): 940-947.
Descargas
Publicado
Cómo citar
Número
Sección
